Partnering and Pipeline
We provide a wide range of R&D opportunities.
Partnering & Pipeline
By 2030, the number of AD and DLB patients are increasing to 4 and 0.5 millions, respectively, in Japan. However, disease-modifying therapeutics remains undeveloped. We supply technologies to define prodromal dementia and support the patients using brain rehabilitation technologies for longevity with healthy brain.
Development of diagnosis technologies for the healthy aging in brain（AMED, Sendai Nishitaga Hospital）
Development for therapeutics for prodromal dementia（Tohoku University, Tottori University, Shiratori Pharmaceutical company）
Supporting healthy brain aging by supplements and foods（Food companies）
Monitoring of brain inflammation to prevent brain attack（Kurume University）
Supporting autism spectrum disorders by brain monitoring and therapy（Fukui Medical University, SBI Pharma）